Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

LNTH vs BMRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LNTH Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

LNTH Overall Winner 6-Pillar Tally: LNTH 6 – 0 BMRA Matrix Metrics: LNTH 9 – 1 BMRA

As of Nov 16, 2026, Lantheus Holdings, Inc (LNTH) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LNTH carries a Unified Composite Score of 43.5/100 (HOLD) at $101.75 (15.4x Forward P/E, 16.9% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin).

  • Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. LNTH 43.5/100 HOLD), LNTH captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (16.9% vs. -125.2% operating margin) and revenue trajectory (+1.5% vs. -8.3% YoY).
  • Technical & Structure Timing Caution: LNTH trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 65.8); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LNTH vs BMRA
LNTH NASDAQ Head-to-Head Winner
Lantheus Holdings, Inc
In Vitro & In Vivo Diagnostic Substances
$101.75
+0.16% 1D
Market Cap $6.6B
TTM Revenue $1.56B
Forward P/E 15.4x
Beta / 30D Vol 0.45β · 5% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 42.0 Fund 49.0 Flow 58.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 66
RSI-14: 65.8 · SMA20: $100.69 · SMA50: $100.34
BMRA NASDAQ
Biomerica Inc
In Vitro & In Vivo Diagnostic Substances
$1.33
-2.32% 1D
Market Cap $6.0M
TTM Revenue $4.3M
Forward P/E N/M
Beta / 30D Vol 0.67β · 62% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.7%), weak momentum, RSI 28
RSI-14: 28.0 · SMA20: $1.62 · SMA50: $1.96

6-Pillar Scorecard Institutional Category Breakdown (LNTH 6 – 0 BMRA)

Columns: Metric · LNTH · BMRA
1. Valuation Multiples LNTH
Forward P/E 15.4x N/M
Trailing P/E 25.3x N/M
PEG Ratio 0.61x N/M
EV / Revenue 4.2x 1.1x
2. Growth & Scale LNTH
Revenue Growth (YoY) +1.5% -8.3%
Earnings Growth (YoY) -19.5% +0.0%
TTM Revenue (USD) $1.56B $4.3M
Market Cap $6.6B $6.0M
3. Profitability & Quality LNTH
Gross Margin 61.3% 0.9%
Operating Margin 16.9% -125.2%
Net Profit Margin 17.3% -115.5%
Return on Equity (ROE) 21.8% -113.8%
4. Balance Sheet & Cash Flow LNTH
Cash Generation (TTM) $387M -$3.2M
Cash Flow Margin 24.8% -73.5%
Net Cash / Leverage $59M Net Cash $1.1M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning LNTH
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 7.2% (4th %ile) N/A (N/A)
Put/Call OI Skew 0.87x (Balanced) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat LNTH
OpEx & R&D Intensity 44.4% of Rev ($694M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LNTH (9) vs BMRA (1)
Institutional Metric LNTH BMRA Criterion Row Edge
Market Capitalization
Scale
$6.6B $6.0M Larger Scale LNTH
Trailing P/E Ratio
Valuation
25.3x N/M Lower Multiple LNTH
Forward P/E Ratio
Valuation
15.4x N/M Lower Multiple LNTH
Revenue Growth (YoY)
Growth
+1.5% -8.3% Higher Growth LNTH
Operating Margin (TTM)
Profitability
16.9% -125.2% Higher Margin LNTH
Net Profit Margin
Profitability
17.3% -115.5% Higher Margin LNTH
Return on Equity (ROE)
Capital Efficiency
21.8% -113.8% Higher ROE LNTH
52-Week Range Position
Momentum
83% ($51–$112) 4% ($1–$3) Stronger Trend LNTH
Beta / 30D Volatility
Risk Regime
0.45β · 5% Vol 0.67β · 62% Vol Lower Realized Risk LNTH
Unified Institutional Score
Composite Signal
43.5 / 100 (HOLD) 44.5 / 100 (HOLD) Higher Composite BMRA
Trailing 12M Revenue (USD)
Operating Scale
$1.56B $4.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
61.3% 0.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.61x PEG · 4.2x EV/Rev N/M PEG · 1.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$387M ($59M Net Cash) -$3.2M ($1.1M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LNTH +30.25 pp
LNTH: +2.06% · BMRA: -28.19%
3M Horizon LNTH +18.46 pp
LNTH: +1.49% · BMRA: -16.97%
6M Horizon LNTH +50.22 pp
LNTH: +9.26% · BMRA: -40.96%
1Y Horizon LNTH +138.42 pp
LNTH: +91.56% · BMRA: -46.86%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period LNTH Revenue BMRA Revenue LNTH Op. Margin BMRA Op. Margin Margin Leader
FY2019 $350M $10M 14.9% -46.4% LNTH
FY2020 $340M $10M -1.2% -41.0% LNTH
FY2021 $430M $10M -14.3% -104.2% LNTH
FY2022 $940M $20M 3.9% -24.0% LNTH
FY2023 $1.30B $10M 28.1% -135.3% LNTH
FY2024 $1.53B $10M 29.8% -117.6% LNTH
FY2025 $1.54B $10M 20.2% -96.7% LNTH
FY2026 N/A $0M N/A -119.5% BMRA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LNTH CONSOLIDATION
97d in phase · OBV DISTRIBUTION
Current IV 7.2%
IV Percentile 4th %ile
Put/Call OI Skew 0.87x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact LNTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BMRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LNTH Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $6.6B market capitalization and 16.9% operating margin.
OpEx & R&D Reinvestment 44.4% of Rev ($694M)
90D Engineering Disclosures 0 Published
BMRA Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.0M market capitalization and -125.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LNTH vs BMRA Key Questions & Quantitative Answers

As of Nov 16, 2026, Lantheus Holdings, Inc (LNTH) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LNTH carries a Unified Composite Score of 43.5/100 (HOLD) at $101.75 (15.4x Forward P/E, 16.9% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin). Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. LNTH 43.5/100 HOLD), LNTH captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (16.9% vs. -125.2% operating margin) and revenue trajectory (+1.5% vs. -8.3% YoY). Technical & Structure Timing Caution: LNTH trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 65.8); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

LNTH leads the Growth & Scale pillar: LNTH posts +1.5% YoY revenue growth and -19.5% YoY earnings growth on $1.56B TTM revenue (61.3% gross margin, 16.9% operating margin), compared with BMRA at -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), LNTH cumulative revenue shifted +340.0% while BMRA shifted +0.0%. In operating R&D and SG&A reinvestment, LNTH deploys 44.4% of Rev ($694M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BMRA.

LNTH screens cheaper on headline valuation multiples. LNTH trades at 15.4x Forward P/E, 25.3x Trailing P/E, 0.61x PEG, and 4.2x EV/Revenue (24.8% FCF margin), whereas BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LNTH (21.8% ROE) versus BMRA (-113.8% ROE) capital efficiency.

In options market volatility and institutional positioning, LNTH carries 7.2% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.87x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.45β · 5% Vol realized risk). By comparison, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.